Univerzita Palackeho V Olomouci

Ustav Experimentalni Botaniky Av Cr, V.v.i.

Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky

Bioapex, S.r.o.

Institute of Experimental Botany of the Academy of Sciences of the Czech Republic

Centre National De La Recherche Scientifique

Freie Universitat Berlin

Institute of Experimental Botany

Uniwersytet W Bialymstoku

Univerzita Palackeho

Institute of Experimental Botany, Academy of Sciences of the Czeck Republic

Biopatterns, S.r.o.

Syngenta Participations Ag

Palacky University Olomouc

Fyziologicky Ustav Av Cr, V.v.i.

Miroslav Strnad

Karel Dolezal

Marek Zatloukal

Lukas Spichal

Vladimir Krystof

Libor Havlicek

Jiri Voller

Lucie Plihalova

Igor Popa

Radek Jorda

Jiri Gruz

René Lenobel

Frank J Massino

Ondrej Plihal

Lucie Szucova

Stefaan Werbrouck

Marian Hajduch

Borivoj Vojtesek

Antonin Sturc

Vaclav Mik

Petr Galuszka

Radoslav Koprna

Jan Holub

Eva Reznickova

Hana Vylicilova

Rene Lenobel

Jitka Ulrichova

Alena Kadlecova

Alena Rajnochova Svobodova

Jitka Vostalova

Jaroslav Nisler

Laurent Meijer

Peter Martin Fischer

Emile R Bisagni

Thomas Schmülling

Tomas Werner

Michel Legraverend

Daniela Moravcová

Algirdas Sackus

Mari&aacute;n Hajd&uacute;ch

Jan Hanus

Vladimir Divoky

Tomas Pospisil

Jana Bibova

Stefan Zahler

Angelika Vollmar

Gabriel Gonzales

Noemi Bucharova

Wolfgang Mikulits

Petr Kanovsky

Martin Hönig

Jana Klaskova

Tomas Gucky

Jacek Witold Morzycki

Johannes Van Staden

Agnieszka Wojtkielewicz

Jana Oklestkova

Lucie Hoffmannova

Petr Cankar

Jaroslav Vesel&yacute;

Ponnusamy Baskaran

Iveta Frysova

Aloka Kumari

Jan Slouka

Vladim&iacute;r Krystof

Marketa Gemrotova

Adeyemi Oladapo Aremu

Jitka Frebortova

Jan Walla

Magdalena Bryksova

Dana Hradecká

Stjepan Uldrijan

Tereza Radosova Muchova

Lenka Zahajska

Petr Mlejnek

Kveta Fuksova

Dardan Klos

Jarmila Balonova

Ludek Frohlich

Egle Arbaciauskiene

Asta Žukauskaite

Neringa Kleiziene

Aurimas Bieliauskas

Thomas Schmulling

Frantisek Skarupa

Marketa Dokonalova

Lucie RÁROVÁ

David Kopecny

Helena Simerska

Gabriele Varvuolyte

Lukas Malina

Barbora Hosikova

Hana Kolarova

Ladislava Vymetalova

Dana Hradeck

Daniela Moravcova

Pavla Binarova

A para-topolin mesylate salt and its crystalline form is disclosed. Cosmetic and therapeutic applications, and compositions containing this compound, are also disclosed. Mesylate salt of para-topolin has a wide range of biological activities, including antioxidative, anti-inflammatory, anti-senescent and anti-aging while showing low toxicity and excellent solubility.

Mesylate salt of para-topolin, compositions containing said salt and use thereof

Heterocyclic nitrogen-containing purine derivatives and their use in the medicinal applications and compositions containing these derivatives is disclosed. A new generation of compounds possessing selective antineurodegenerative properties on neuronal cells and tissues and that can be particularly used in the treatment and prophylaxis of neurodegenerative disease, particularly in the treatment and prophylaxis of Parkinson's disease is also disclosed.

Heterocyclic nitrogen-containing purine derivatives, pharmaceutical preparations containing these derivatives and their use in neuroprotection

The invention relates to N,N-disubstituted-9-(2-oxacycloalkyl)-9H-purine-2, 6-diamine derivatives and their use as drugs and cosmetics. The compounds of the present invention exhibit a number of biological activities associated with oxidative stress inhibition, especially anti-aging, anti-inflammatory and anti-neurodegenerative biological activities. The invention also relates to cosmetic and pharmaceutical compositions containing such derivatives as active agents.

9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders

5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidine derivatives of formula I that are effective inhibitors of kinases and exhibit strong antiproliferative and proapoptotic properties on lymphoma cells. Derivatives in the treatment of blood hyperproliferative diseases, such as Non-Hodgkin lymphomas are also disclosed.

5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidines for treatment of lymphoma

The present invention relates to novel 2,6-disubstituted-9-cyclopentyl-9H-purines of general formula I, capable of inhibiting the activity of kinases such as FLT3, CDKs and PDGFRs in cancer and other related proliferative diseases. The invention further includes pharmaceutical compositions containing the 2,6-disubstituted-9-cyclopentyl-9H-purines. Compounds of the present invention can be used as active ingredients of a pharmaceutical compositions for treating acute myeloid leukemia (AML).

2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions

Adenine derivatives substituted at the C2, N6, and N9 purine positions having antisenescent and combined photoprotective UVA/UVB effects. These substances are particularly suitable as anti-senescent and UV-photoprotective component in cosmetic preparations, plant protection preparations and in preparations for the treatment/application of tissue cultures. 

Adenine derivatives and their use as UV-photoprotective agents

The invention relates to substituted 6-anilino-9-heterocyclylpurine derivatives of formula I wherein R denotes one to five substituents independently selected from the group hydrogen, halogen, hydroxy, amino, alkyloxy and alkyl group, R2 is selected from the group comprising amino, halogen, hydroxy, thio, and alkylthio group, Cyc is five- or six-membered heterocyclic ring containing one oxygen atom. The derivatives are useful for inhibition of plant stress.

Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress

6-aryl-9-glycosidpurines of general formula I and pharmaceutically acceptable salts thereof with alkali metals, ammonia, amines, or addition salts with acids, wherein

6-aryl-9-glycosylpurines and use thereof

6-aryl-9-glycosidpurines of general formula I and pharmaceutically acceptable salts thereof with alkali metals, ammonia, amines, or addition salts with acids, whereinGly represents &#x3b2;-D-arabinofuranosyl or &#x3b2;-D-2'-deoxyribofuranosyl,Ar represents benzyl or furfuryl, each of which can be unsubstituted or substituted by one or more, preferably one to three, substituents selected from the group comprising hydroxyl, alkyl, halogen, alkoxy, amino, mercapto, carboxyl, cyano, amido, sulfo, sulfamido, acyl, acylamino, acyloxy, alkylamino, dialkylamino, alkylmercapto, trifluoromethyl, trifluoromethoxy, for use as antisenescent and UV protective compounds in animals.

6,8-Disubstituted-9-(heterocyclyl)purines for use in pharmaceutical and cosmetic compositions and applications are provided. These 6,8-disubstituted-9-(heterocyclyl)purines have a wide range of biological activities, including for example antioxidant, anti-inflammatory, anti-senescent, anti-aging, as well as well as other activities which are especially useful in pharmaceutical and cosmetic applications. Compositions may include additional excipients and auxiliary substances. Methods of treatment of animals, mammals, plants, cells, yeast, and cells in tissue culture are also disclosed.

6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications

Substituted 1,2,3-thiadiazol-5yl-urea derivatives, their use as anti-senescence and anti-stress factors of plant cells, organs and the whole plant, and preparations containing these derivatives.

1,2,3-thiadiazol-5yl-urea derivatives, use thereof for regulating plant senescence and preparations containing these derivatives

5-substituted-7-[4-(2-pyridyl)phenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidines are potent inhibitors of protein kinases, especially cyclin-dependent kinases such as CDK2 and CDK5, and display antileukemic, pro-apoptotic, antiangiogenic and anticancer activities. The invention also relates to processes for their preparation, to pharmaceutical compositions and to their use as medicaments, particularly in the treatment of disorders involving cell proliferation, apoptosis, angiogenesis and inflammation, such as leukemia and metastatic solid cancer.

5-substituted 7- [4-(2-pyridyl)phenylmethylamino] -3-isopropylpyrazolo4,3-D]pyrimidine derivatives, use thereof as medicaments, and pharmaceutical compositions

The invention relates to 6-substituted 9-halogenalkyl purine derivatives of the general formula I wherein R6 is selected from the group comprising &#x2014;NH-furfuryl, &#x2014;NH-(4-hydroxy-3-methylbut-2-en-1-yl), &#x2014;NH-(3-methylbut-2-en-1-yl), &#x2014;NH-(4-hydroxy-3-methylbutyl), &#x2014;NH-(4-hydroxy-1,3-dimethylbut-2-en-1-yl), &#x2014;NH-(4-hydroxy-1,3-dimethylbutyl), &#x2014;NH-benzyl, &#x2014;NH-phenyl, wherein benzyl, furfuryl and phenyl can be unsubstituted or optionally substituted with 1 to 3 substituents selected from the group comprising hydroxy, halogen, methyl and methoxy, and R9 is selected from the group comprising C-Calkyl or C-Calkenyl wherein each of the groups is substituted with one or more halogen atoms, for use in the regulation of growth and development of plant cells, organs and/or whole plants. The invention also relates to preparations containing these derivatives and to novel to 6-substituted 9-halogenalkyl purines.

Use of 6-substituted 9-halogenalkyl purines for regulation of growth and development of whole plants, plant cells and plant organs; novel 6-substituted 9-halogenalkyl purines

The invention relates to substitution derivatives of N-benzyladenosine-5'-monophosphate of the general formula I, wherein (R)represents 1 to 4 substituents (n is in the range 1-4), which can be the same or different, and R is selected from the group comprising Cto Calkyl, Cto Calkoxy, amino, halogen, hydroxy, mercapto and nitro groups, and the pharmaceutically acceptable salts thereof. This invention also relates to methods of their preparation, their use as medicaments and in other biotechnological applications, and a therapeutic composition containing these derivatives.

[object Object]

The invention relates to new substituted 6-(2-aminobenzylamino)purines, represented by the general formula I, which can be used in CDK inhibition, in particular, in the treatment of viral infections and diseases involving cell proliferation. The invention further includes pharmaceutical preparations containing substituted 6-(2-aminobenzylamino)purines.

Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds

Growing community of inventors

Olomouc, Czechia

Miroslav Strnad